Progress in molecular mechanisms of tumor metastasis and angiogenesis

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3327-3333

  Harlozinska, Antonina ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Angiogenesis; Cell adhesion; Cell migration; Local proteolysis; Metastatic cascade; Review

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; APOPTOSIS INHIBITOR; BATIMASTAT; BEVACIZUMAB; CADHERIN; CATENIN; CELL ADHESION MOLECULE; CHEMOKINE; COLLAGENASE; CYSTEINE PROTEINASE; ENDOSTATIN; GELATINASE; GFA 116; IMMUNOGLOBULIN; INTEGRIN RECEPTOR; MATRIX METALLOPROTEINASE; NERVE CELL ADHESION MOLECULE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE INHIBITOR; SERINE PROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER INVASION; CELL ADHESION; CELL MIGRATION; CELL MOTILITY; CLINICAL TRIAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; METASTASIS; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOPODIUM; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL ADHESION; CELL MOVEMENT; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 23344434132     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Tait CR, Dodwell D and Horgan K: Do metastases metastasize? J Pathol 203: 515-518, 2004.
2. Engers R and Gabbert HE: Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J Cancer Res Clin Oncol 126: 682-692, 2000.
3. Harlozinska-Szmyrka A: Molecular aspects of carcinogenesis. In: International Intensive Course in Oncology ERASMUS'99, Recent Advances in the Knowledge of Cancer, (Kornafel J and Chybicka A, eds.), Wroclaw Med Univ, Poland, pp. 598-616, 1999.
4. Marcel MM, Van Roy FM and Bracke ME: How and when do tumor cells metastasize? Crit Rev Oncogen 4: 559-594, 1993.
5. Plesnicar S: Mechanisms of development of metastases. Crit Rev Oncogen 1: 175-194, 1989.
6. Woodhouse EC, Chuaqui RF and Liotta LA: General mechanisms of metastasis. Cancer 80: 1529-1537, 1997.
7. Brennan P: Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 23: 381-387, 2002.
8. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Rev 3: 453-458, 2003.
9. Mareel M and Leroy A: Clinical, cellular and molecular aspects of cancer invasion. Physiol Rev 83: 337-376, 2003.
10. Siegel G and Malmsten M: The role of the endothelium in inflammation and tumor metastasis. Int J Microcirc 17: 257-272, 1997.
11. Sottile J: Regulation of angiogenesis by extracellular matrix. Bioch Bioph Acta 1654: 13-22, 2004.
12. Marcel MM, Bracke ME, Van Roy FM and de Baetselier P: Molecular mechanisms of cancer invasion. Encycl Cancer 2: 1072-1083, 1997.
13. Scott GK: Proteinases and proteinase inhibitors in tumour cell growth and metastasis. Cancer J 10: 80-86, 1997.
14. Hunter KW: Host genetics and tumour metastasis. Br J Cancer 90: 752-755, 2004.
15. Porter PL: Molecular markers of tumor initiation and progression. Curr Opin Genet Develop 11: 60-63, 2001.
16. Van't Veer LJ and Weigelt B: Road map to metastasis. Nature Med 9: 999-1000, 2003.
17. Van Kempen LCLT, Ruiter DJ, van Muijen GNP and Coussens LM: The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82: 539-548, 2003.
18. Weigelt B, Glas AM, Wessels LFA, Witteveen AT, Peterse JL and Van't Veer LJ: Gene expression profiles of primary breast tumors maintained in distant metastases. PNAS 100: 15901-15905, 2003.
19. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nature Rev 2: 563-572, 2002.
20. Siegel G, Malmsten M and Klüßendorf D: Tumor cell locomotion and metastatic spread. Microsc Res Tech 43: 276-282, 1998.
21. Christofori G: Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression. EMBO J 22: 2318-2323, 2003.
22. Jiang WG, Puntis MCA and Hallett MB: Molecular and cellular basis of cancer invasion and metastasis: implications for treatment. Br J Surg 81: 1576-1590, 1994.
23. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003.
24. Perl AK, Wilgenbus P, Dahl U, Semb H and Christofori G: A casual role for E-cadherin in the transition from adenoma to carcinoma. Nature 592: 190-193, 1998.
25. Nakashima T, Huang C, Liu D, Kameyama K, Masuya D, Kobayashi S, Kinoshita M and Yokomise H: Neural-cadherin expression associated with angiogenesis in non-small-cell lung cancer patients. Br J Cancer 88: 1727-1733, 2003.
26. McCawley LJ and Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Molec Med Today 6: 149-156, 2000.
27. Murray GI: Matrix metalloproteinases: multifunctional group of molecules. J Pathol 195: 135-137, 2001.
28. Nabeshima K, Inoue T, Shimao Y and Sameshima T: Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Intern 52: 255-264, 2002.
29. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinases inhibitors and cancer: trials and tribulations. Science 295: 2387-2392, 2002.
30. Polette M, Nawrocki-Raby B, Gilles C, Clavel C and Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 49: 179-186, 2004.
31. Masaki T, Sugiyama M, Matsuoka H, Abe N, Izumisato Y, Sakamoto A and Atomi Y: Matrix metalloproteinases may contribute compensationally to tumor invasion in T1 colorectal carcinomas. Anticancer Res 23: 4169-4173, 2003.
32. Wall SJ, Jiang Y, Muschel RJ and DeClerck YA: Meeting Report: Proteases, extracellular matrix, and cancer: An AACR Special Conference in Cancer Research. Cancer Res 63: 4750-4755, 2003.
33. Stamenkovic I: Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 200: 448-464, 2003.
34. Macaulay VM, O'Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P and Talbot DC: Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5: 513-520, 1999.
35. Wang JM, Deng X, Gong W and Su S: Chemokines and their role in tumor growth and metastasis. J Immunol Meth 220: 1-17, 1998.
36. Felding-Habermann B: Integrin adhesion receptors in tumor metastasis. Clin Exper Metast 20: 203-213, 2003.
37. Hood JD and Cheresh DA: Role of integrins in cell invasion and migration. Nature Rev 2: 91-100, 2002.
38. Entschladen F, Drell TL 4th, Lang K, Joseph J and Zaenker KS: Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 5: 254-258, 2004.
39. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metast Rev 22: 395-403, 2003.
40. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA and Massague J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
41. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R and Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002.
42. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R and Klein CA: From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100: 7737-7742, 2003.
43. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D and Foekens JA: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679, 2005.
44. Hart IR: Perspective: tumour spread-the problems of latency. J Pathol 187: 91-94, 1999.
45. Coomber BL, Yu JL, Fathers KE, Plumb C and Rak JW: Angiogenesis and the role of epigenetics in metastasis. Clin Exper Metast 20: 215-227, 2003.
46. Ellis LM and Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 32A: 2451-2460, 1996.
47. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 21: 505-515, 2000.
48. Zetter BR: Angiogenesis and tumor metastasis. Ann Rev Med 49: 407-424, 1998.
49. Strohmeyer D, Strauss F, Rossing C, Roberts C, Kaufmann O, Bartsch G and Effert P: Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24: 1797-1804, 2004.
50. Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G, Glaser F and Kunze E: Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24: 2745-2756, 2004.
51. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
52. Li J, Zhang YP and Kirsner RS: Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 60: 107-114, 2003.
53. Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wojcik E, Van Dalen A and Einarsson R: Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res 24: 1149-1158, 2004.
54. Dworak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20: 4368-4380, 2002.
55. Klagsbrun M: Angiogenesis and cancer AACR Special Conference in Cancer Research. Cancer Res 59: 487-490, 1999.
56. Moon WS, Chang K and Tarnawski AS: Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol 35: 424-429, 2004.
57. Pepper MS: Lymphangiogenesis and tumor metastasis: Myth or reality? Clin Cancer Res 7: 462-468, 2001.
58. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY and Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nature Med 10: 145-147, 2004.
59. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD and Sebti SM: Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 64: 3586-3592, 2004.
60. Paget S: The distribution of secondary growths in cancer of the breast. Lancet 1: 571-573, 1889.